No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects

Diabetes, Obesity and Metabolism

Volumn 14, Issue 10, 2012, Pages 937-943

  Smulders, R A ^a   Zhang, W ^b   Veltkamp, S A ^a   van Dijk, J ^a   Krauwinkel, W J J ^a   Keirns, J ^b   Kadokura, T ^c  

^a Astellas Pharma Global Development   (Netherlands)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^c ASTELLAS PHARMA INC   (Japan)

Author keywords

Ipragliflozin; Sodium glucose co transporter 2 (SGLT2) inhibitor; Type 2 diabetes mellitus

Indexed keywords

CREATINE KINASE; GLIMEPIRIDE; GLUCOSE; IPRAGLIFLOZIN; PIOGLITAZONE; SITAGLIPTIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; SIDE EFFECT; SINGLE DRUG DOSE;

EID: 84865990718     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01624.x     Document Type: Article

References (18)

1. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
2. Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res 1994; 30: 187-228.
3. Korytkowski M, Thomas A, Reid L, Tedesco MB, Gooding WE, Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care 2002; 25: 1607-1611.
4. Smith U. Pioglitazone: mechanism of action. Int J Clin Pract Suppl 2001; 121: 13-18.
5. Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab 2009; 23: 479-486.
6. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-342.
7. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 2009; 53: 875-883.
8. Wright EM. Renal Na(+)-glucose co-transporters. Am J Physiol Renal Physiol 2001; 280: F10-F18.
9. Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010; 70: 377-385.
10. Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract 2008; 62: 1279-1284.
11. Oku A, Ueta K, Arakawa K et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999; 48: 1794-1800.
12. Veltkamp SA, Kadokura T, Krauwinkel WJ, Smulders RA. Effect of ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Investig 2011; 31: 839-851.
13. Kadokura T, Saito M, Utsuno A et al. Ipragliflozin (ASP1941), a selective sodium-dependent glucose co transporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects. Diabetol Int 2011; 2: 172-182.
14. Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2011; 13: 1219-1227.
15. Yun HY, Park HC, Kang W, Kwon KI. Pharmacokinetic and pharmacodynamic modelling of the effects of glimepiride on insulin secretion and glucose lowering in healthy humans. J Clin Pharm Ther 2006; 31: 469-476.
16. Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmöller J. Effect of genetic polymorphisms in cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs. Clin Pharmacokinet 2005; 44: 1209-1225.
17. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010; 12: 648-658.
18. Amaryl Summary of Product Characteristics. Available from URL: http://products.sanofi.us/amaryl/amaryl.pdf. Accessed January 2012.